Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), reported first-half 2026 revenue of $949,000, up from $773,000 in the prior-year period, while committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (“CMC”) program for a U.S.-based biopharmaceutical company, with approximately $650,000 in cash payments and advances received and substantive activities underway while a definitive agreement remains under negotiation. The program is intended to support an investigational drug product toward a U.S. investigational new drug (“IND”) submission and Phase III clinical development. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026.
Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million a year earlier, while net income was approximately $1.6 million versus a net loss of approximately $4.1 million, primarily reflecting a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. Cash, cash equivalents and restricted cash totaled approximately $2.9 million as of June 30, 2026. The company continues to advance its PC111 and NanoAbs therapeutic programs and will host an investor webinar Aug. 26, 2026, to discuss recent developments, financial performance and upcoming milestones.
To view the full press release, visit https://nnw.fm/Be7Ky
About Scinai Immunotherapeutics.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN